Methods: This study was approved by the Xavier University of Louisiana Institutional Review Board. Eligible patients were aged 40 – 75 years old, with at least one primary care visit to the University Medical Center New Orleans Infectious Disease Center between December 2013 and November 2015. Statin eligibility was determined based on the 2013 cholesterol guidelines. Descriptive statistics and multiple logistic regression were used to analyze demographics and secondary objectives.
Results: A random sample of 250 patients were reviewed (62% male, 80% African-American). From this sample, 23 were excluded due to missing data. A total of 127 patients were determined to be statin-eligible; main reasons for statin-ineligibility included: 10-year risk <7.5% (n=64) and low-density lipoprotein <70 mg/dL (n=29). Among statin-eligible patients, 59.8% (n=76) were prescribed a statin. Patient factors associated with increased statin prescribing included increasing age (OR 1.34 (0.79-2.26)) and female gender (OR 1.66 (0.75-3.67)), whereas having less subsidized insurance was associated with decreased statin prescribing (OR 0.96 (0.74-1.24); none of these factors reached statistical significance. Of the statin-eligible patients who did not receive a statin, 82% had a high 10-year risk ≥ 7.5%; 35.3% (n=18) of these patients were persistently viremic (>400 copies/mL) throughout the study period.
Conclusion: Despite the majority of statin-eligible patients receiving a statin, the results from this study demonstrate an opportunity for improved patient care. The inclusion of an automatically calculated risk assessment may improve statin prescribing practices for HIV patients.
M. Frontini, None
D. Sarpong, None
J. Halperin, None
L. Mihm, None
K. Rapp, None